These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 17475966)

  • 21. Utility of 18F-FDG PET and contrast-enhanced CT scan in the assessment of residual liver metastasis from colorectal cancer following adjuvant chemotherapy.
    Carnaghi C; Tronconi MC; Rimassa L; Tondulli L; Zuradelli M; Rodari M; Doci R; Luttmann F; Torzilli G; Rubello D; Al-Nahhas A; Santoro A; Chiti A
    Nucl Med Rev Cent East Eur; 2007; 10(1):12-5. PubMed ID: 17694495
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis.
    Lin C; Itti E; Haioun C; Petegnief Y; Luciani A; Dupuis J; Paone G; Talbot JN; Rahmouni A; Meignan M
    J Nucl Med; 2007 Oct; 48(10):1626-32. PubMed ID: 17873129
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased metabolic activity of indolent liver metastases after resection of a primary colorectal tumor.
    Scheer MG; Stollman TH; Vogel WV; Boerman OC; Oyen WJ; Ruers TJ
    J Nucl Med; 2008 Jun; 49(6):887-91. PubMed ID: 18483084
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases.
    Fong Y; Saldinger PF; Akhurst T; Macapinlac H; Yeung H; Finn RD; Cohen A; Kemeny N; Blumgart LH; Larson SM
    Am J Surg; 1999 Oct; 178(4):282-7. PubMed ID: 10587184
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of staging with 18F-FDG-PET on outcome of patients with stage III non-small cell lung cancer: PET identifies potential survivors.
    Eschmann SM; Friedel G; Paulsen F; Reimold M; Hehr T; Scheiderbauer J; Budach W; Kotzerke J; Bares R
    Eur J Nucl Med Mol Imaging; 2007 Jan; 34(1):54-9. PubMed ID: 16896660
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of 18F-FDG PET/CT on therapeutic decisions in patients with colorectal cancer and liver metastases.
    Georgakopoulos A; Pianou N; Kelekis N; Chatziioannou S
    Clin Imaging; 2013; 37(3):536-41. PubMed ID: 23116727
    [TBL] [Abstract][Full Text] [Related]  

  • 27. F18-FDG-PET evaluation of patients for resection of colorectal liver metastases.
    Huguet EL; Old S; Praseedom RK; Balan KK; Gibbs P; Jamieson NV
    Hepatogastroenterology; 2007 Sep; 54(78):1667-71. PubMed ID: 18019690
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FDG-PET for the pre-operative evaluation of colorectal liver metastases.
    Arulampalam TH; Francis DL; Visvikis D; Taylor I; Ell PJ
    Eur J Surg Oncol; 2004 Apr; 30(3):286-91. PubMed ID: 15028310
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic value of initial fluorodeoxyglucose-PET in esophageal cancer: a prospective study.
    Cheze-Le Rest C; Metges JP; Teyton P; Jestin-Le Tallec V; Lozac'h P; Volant A; Visvikis D
    Nucl Med Commun; 2008 Jul; 29(7):628-35. PubMed ID: 18528185
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic aspects of 18F-FDG PET kinetics in patients with metastatic colorectal carcinoma receiving FOLFOX chemotherapy.
    Dimitrakopoulou-Strauss A; Strauss LG; Burger C; Rühl A; Irngartinger G; Stremmel W; Rudi J
    J Nucl Med; 2004 Sep; 45(9):1480-7. PubMed ID: 15347714
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PET-FDG as predictor of therapy response in patients with colorectal carcinoma.
    Dimitrakopoulou-Strauss A; Strauss LG; Rudi J
    Q J Nucl Med; 2003 Mar; 47(1):8-13. PubMed ID: 12714949
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of ¹⁸F-FDG-PET in decision making for liver metastectomy of colorectal cancer.
    McLeish AR; Lee ST; Byrne AJ; Scott AM
    ANZ J Surg; 2012; 82(1-2):30-5. PubMed ID: 22507492
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of FDG-PET in the selection of patients with colorectal liver metastases.
    Wiering B; Krabbe PF; Dekker HM; Oyen WJ; Ruers TJ
    Ann Surg Oncol; 2007 Feb; 14(2):771-9. PubMed ID: 17086488
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PET-CT accurately predicts the pre-operative characteristics of colorectal hepatic metastases.
    Jones C; Badger SA; McKie LD; Diamond T; Taylor MA; Lynch TB
    Eur J Surg Oncol; 2012 Dec; 38(12):1184-8. PubMed ID: 22883963
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular mechanisms of [18F]fluorodeoxyglucose accumulation in liver cancer.
    Izuishi K; Yamamoto Y; Mori H; Kameyama R; Fujihara S; Masaki T; Suzuki Y
    Oncol Rep; 2014 Feb; 31(2):701-6. PubMed ID: 24297035
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Response to intra-arterial oncolytic virotherapy with the herpes virus NV1020 evaluated by [18F]fluorodeoxyglucose positron emission tomography and computed tomography.
    Sze DY; Iagaru AH; Gambhir SS; De Haan HA; Reid TR
    Hum Gene Ther; 2012 Jan; 23(1):91-7. PubMed ID: 21895536
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PET-CT as a predictor of outcome in resectable colorectal liver metastases.
    Jones C; Badger SA; Stevenson M; Diamond T; McKie LD; Taylor MA; Wilson RH; Lynch TB
    Eur J Gastroenterol Hepatol; 2014 Apr; 26(4):466-72. PubMed ID: 24445726
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.
    Chen W; Cloughesy T; Kamdar N; Satyamurthy N; Bergsneider M; Liau L; Mischel P; Czernin J; Phelps ME; Silverman DH
    J Nucl Med; 2005 Jun; 46(6):945-52. PubMed ID: 15937304
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of FDG-PET in surgical management of patients with colorectal liver metastases.
    Teague BD; Morrison CP; Court FG; Chin VT; Costello SP; Kirkwood ID; Maddern GJ
    ANZ J Surg; 2004 Aug; 74(8):646-52. PubMed ID: 15315564
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlation between 18F-FDG uptake on PET and molecular biology in metastatic pulmonary tumors.
    Kaira K; Okumura T; Ohde Y; Takahashi T; Murakami H; Oriuchi N; Endo M; Kondo H; Nakajima T; Yamamoto N
    J Nucl Med; 2011 May; 52(5):705-11. PubMed ID: 21498541
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.